Liu Jun, Liu Ke, Cao Fang, Hu Pingsheng, Bi Feng, Liu Siye, Jian Lian, Zhou Jumei, Nie Shaolin, Lu Qiang, Yu Xiaoping, Wen Lu
Department of Diagnostic Radiology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China.
Department of Radiotherapy, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China.
Abdom Radiol (NY). 2025 Jun;50(6):2388-2400. doi: 10.1007/s00261-024-04710-0. Epub 2024 Dec 4.
Individual prognosis assessment is of paramount importance for treatment decision-making and active surveillance in cancer patients. We aimed to propose a radiomic model based on pre- and post-therapy MRI features for predicting disease-free survival (DFS) in locally advanced rectal cancer (LARC) following neoadjuvant chemoradiotherapy (nCRT) and subsequent surgical resection.
This retrospective study included a total of 126 LARC patients, which were randomly assigned to a training set (n = 84) and a validation set (n = 42). All patients underwent pre- and post-nCRT MRI scans. Radiomic features were extracted from higher resolution T2-weighted images. Pearson correlation analysis and ANOVA or Relief were utilized for identifying radiomic features associated with DFS. Pre-treatment, post-treatment, and delta radscores were constructed by machine learning algorithms. An individualized nomogram was developed based on significant radscores and clinical variables using multivariate Cox regression analysis. Predictive performance was evaluated by the C-index, calibration curve, and decision curve analysis.
The results demonstrated that in the validation set, the clinical model including pre-surgery carcinoembryonic antigen (CEA), chemotherapy after radiotherapy, and pathological stage yielded a C-index of 0.755 (95% confidence interval [CI]: 0.739-0.771). While the optimal pre-, post-, and delta-radscores achieved C-indices of 0.724 (95%CI: 0.701-0.747), 0.701 (95%CI: 0.671-0.731), and 0.625 (95%CI: 0.589-0.661), respectively. The nomogram integrating pre-surgery CEA, pathological stage, alongside pre- and post-nCRT radscore, obtained the highest C-index of 0.833 (95%CI: 0.815-0.851). The calibration curve and decision curves exhibited good calibration and clinical usefulness of the nomogram. Furthermore, the nomogram categorized patients into high- and low-risk groups exhibiting distinct DFS (both P < 0.0001).
The nomogram incorporating pre- and post-therapy radscores and clinical factors could predict DFS in patients with LARC, which helps clinicians in optimizing decision-making and surveillance in real-world settings.
个体预后评估对于癌症患者的治疗决策和主动监测至关重要。我们旨在提出一种基于治疗前和治疗后MRI特征的放射组学模型,用于预测局部晚期直肠癌(LARC)患者在新辅助放化疗(nCRT)及后续手术切除后的无病生存期(DFS)。
这项回顾性研究共纳入126例LARC患者,随机分为训练集(n = 84)和验证集(n = 42)。所有患者均接受了nCRT治疗前和治疗后的MRI扫描。从高分辨率T2加权图像中提取放射组学特征。采用Pearson相关分析和方差分析或Relief法来识别与DFS相关的放射组学特征。通过机器学习算法构建治疗前、治疗后和差值放射学评分。使用多变量Cox回归分析,基于显著的放射学评分和临床变量开发个性化列线图。通过C指数、校准曲线和决策曲线分析评估预测性能。
结果表明,在验证集中,包括术前癌胚抗原(CEA)、放疗后化疗和病理分期的临床模型的C指数为0.755(95%置信区间[CI]:0.739 - 0.771)。而最佳的治疗前、治疗后和差值放射学评分的C指数分别为0.724(95%CI:0.701 - 0.747)、0.701(95%CI:0.671 - 0.731)和0.625(95%CI:0.589 - 0.661)。整合术前CEA、病理分期以及nCRT治疗前和治疗后放射学评分的列线图获得了最高的C指数0.833(95%CI:0.815 - 0.851)。校准曲线和决策曲线显示列线图具有良好的校准度和临床实用性。此外,列线图将患者分为高风险和低风险组,两组的DFS有显著差异(均P < 0.0001)。
纳入治疗前和治疗后放射学评分及临床因素的列线图能够预测LARC患者的DFS,有助于临床医生在实际临床环境中优化决策和监测。